cibinetide and Erythromelalgia

cibinetide has been researched along with Erythromelalgia* in 3 studies

Reviews

1 review(s) available for cibinetide and Erythromelalgia

ArticleYear
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:4

    Painful peripheral neuropathy is a common, difficult-to-treat complication associated with a variety of diseases, including diabetes mellitus and sarcoidosis. It is caused by damage of small and autonomic nerve fibers, resulting in potentially debilitating symptoms of neuropathic pain and autonomic dysfunction. The limited efficacy of current treatment options dictates a rationalized design of novel compounds.. The authors present the recent data from two Phase II clinical trials on ARA290, an erythropoietin derivative with tissue protective and healing properties that does not stimulate erythropoiesis. ARA 290 treatment was consistently associated with a significant improvement of neuropathic pain symptoms in sarcoidosis patients, evidenced by a decrease in pain scores on validated questionnaires. Moreover, ARA 290 treatment resulted in significant increases in corneal nerve fibers, improved sensory pain thresholds, improved quality of life and physical functioning.. Current treatment modalities of neuropathy are based on a trial-and-error approach, have limited efficacy and come with significant side effects. Given the excellent safety profile while reducing neuropathy symptoms, the prospects of ARA 290 treatment in sarcoid neuropathy seem promising. The long-lasting beneficial effects of ARA 290 on both pain-related and non-pain-related symptoms in sarcoidosis patients prompt additional studies on potential disease-modifying properties of ARA 290.

    Topics: Analgesics; Animals; Erythromelalgia; Humans; Neuralgia; Oligopeptides; Sarcoidosis; Treatment Outcome

2014

Trials

1 trial(s) available for cibinetide and Erythromelalgia

ArticleYear
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
    Molecular medicine (Cambridge, Mass.), 2013, Nov-08, Volume: 19

    Small nerve fiber loss and damage (SNFLD) is a frequent complication of sarcoidosis that is associated with autonomic dysfunction and sensory abnormalities, including pain syndromes that severely degrade the quality of life. SNFLD is hypothesized to arise from the effects of immune dysregulation, an essential feature of sarcoidosis, on the peripheral and central nervous systems. Current therapy of sarcoidosis-associated SNFLD consists primarily of immune suppression and symptomatic treatment; however, this treatment is typically unsatisfactory. ARA 290 is a small peptide engineered to activate the innate repair receptor that antagonizes inflammatory processes and stimulates tissue repair. Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms. In addition to improved patient-reported symptom-based outcomes, ARA 290 administration was also associated with a significant increase in corneal small nerve fiber density, changes in cutaneous temperature sensitivity, and an increased exercise capacity as assessed by the 6-minute walk test. On the basis of these results and of prior studies, ARA 290 is a potential disease-modifying agent for treatment of sarcoidosis-associated SNFLD.

    Topics: Cornea; Drug Administration Schedule; Erythromelalgia; Exercise Test; Female; Humans; Injections, Subcutaneous; Male; Microscopy, Confocal; Middle Aged; Nerve Fibers; Oligopeptides; Sarcoidosis

2013

Other Studies

1 other study(ies) available for cibinetide and Erythromelalgia

ArticleYear
Editorial.
    Molecular medicine (Cambridge, Mass.), 2013, Nov-08, Volume: 19

    Topics: Cornea; Erythromelalgia; Female; Humans; Male; Oligopeptides; Sarcoidosis

2013